和铂医药2024年实现全年总收入2.74亿元人民币,盈利约1941万元,连续两年实现盈利。公司现金及现金等价物约12亿元人民币,财务状况稳健。2024年净现金流入高达2.21亿元,创历史新高。公司在免疫和炎症性疾病、肿瘤等领域拥有多款高度差异化的创新候选药物,包括FcRn抗体巴托利单抗、长效TSLP抗体和新一代CTLA-4抗体普鲁苏拜单抗等。其中,巴托利单抗已递交上市申请,长效TSLP抗体IND...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.